"We are proud that leading organizations such as ISB continue to rely on our high-quality and high-throughput sequencing services to conduct large-scale disease studies," said Dr. Clifford Reid, Complete Genomics chairman, president and CEO. "In 2011, we anticipate that many more researchers will look to complete human genome sequencing to help with their studies of disease, and we look forward to working with the research community to continue to provide accurate, consistent and research-ready data. We currently have the ability to sequence and analyze more than 400 complete human genomes per month, and expect this capacity to increase between two- and threefold in 2011."About the Institute for Systems Biology
The Institute For Systems Biology Places A Third Order For Sequencing Services With Complete Genomics, Includes 615 Genomes
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.